San Diego—The antibiotic fidaxomicin is “highly effective” for treating Clostridium difficile, including in patients with recurrent infection and inflammatory bowel disease, new research shows.
Fidaxomicin (Dificid, Merck) is a macrocytic antibiotic with activity against specific anaerobic gram-positive bacteria, approved for the treatment of C. difficile infection (CDI). Phase III trials showed that fidaxomicin is noninferior to vancomycin for clinical cure and is superior